Many lines of study have postulated that a reduction in SHBG levels in patients with metabolic syndrome plays a role in the development of NAFLD, which is effectively the hepatic manifestation of metabolic syndrome. This evidence concerns the gene SHBG and metabolic dysfunction-associated steatotic liver disease.